25 results for "Transplant"
This study is looking at the effect of the drug on the kidney function after transplantation.
This study is looking at the effect of the drug on the kidney function after transplantation.
When receiving a liver transplant, patients are required to take numerous immunosuppressive drugs. This study will look at the safety and effectiveness of taking everolimus with tacrolimus (another immunosuppressive drug) to see if these two drugs help lower your chances of getting cancer in your new liver versus taking tacrolimus and mycophenolic acid (Myfortic®), mycophenolate mofetil (CellCept®), or azathioprine (Imuran®) after having a liver transplant.
This study is intended to evaluate if there is injury to the liver in liver transplant patients.
The OrganOx metra® device may be a new way of storing (preserving) the liver prior to transplantation. Currently this machine is only intended for investigational use and is not commercially available in the United States. The device uses a method to store the liver at normal body temperature during transport after it has been removed from the donor. The goal is to determine if this method may improve the outcome of transplant over the traditional “cold storage” method.
This study is looking at the effect of the drug on the RSV infection after lung transplantation.
The purpose of this study is to determine the usefulness of the T-SPOT.CMV lab test and the T-SPOT.PRT lab test during the 12 months following kidney transplantation. These lab tests monitor your body’s responses to specific T-cell markers that help identify the existence of infection and/or identify body changes that may suggest a rejection of the transplant.
CMV infections are actually very common in our population, however our immune systems keep them from ever being an issue. They become a problem for transplant patients because of the immunosuppressive drugs they must take during their recovery period post-transplant.
Sorafenib is approved by the FDA for treatment of patients with advanced kidney cancer and advanced unresectable HCC. It is not known whether sorafenib, the study medication, is effective in preventing cancer recurrence in high risk patients following liver transplantation. This study’s purpose is to see if sorafenib is safe and effective in these high risk patients.
The purpose of this study is to determine if there is a link between liver cancer recurrences after liver transplant, in a specific population of patients who have received TACE therapy.
This is a clinical trial that will compare survival and sickle related outcomes in adolescents and young adults with severe sickle cell disease after bone marrow transplantation and standard of care. The primary outcome is 2-year overall survival.
The objective of the study is to evaluate whether the 50cc TAH-t can safely support, and provide probably benefit to, transplant-eligible pediatric patients (aged 10-18 years) and adult patients (aged 19-75 years) at imminent risks of death from biventricular failure without experiencing permanent disabling, stroke-related deficits.
This study is testing the use of an antibiotic called Vancomycin to treat the recurrence of primary sclerosing cholangitis in liver transplant patients.
This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Before transplant, stem cells are taken from patients and stored. Patients then receive high doses of chemotherapy to kill cancer cells and make room for healthy cells. After treatment, the stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Ibrutinib is a drug that may stop the growth of cancer cells by blocking a protein that is needed for cell growth. It is not yet known whether adding ibrutinib to chemotherapy before and after stem cell transplant may help the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma.
The purpose of this study is to determine if the addition of Daratumumab to Lenalidomide-Bortezomib-Dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR) by the time of completion of post autologous stem cell transplantation (ASCT) consolidation treatment, compared with RVd alone.
The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will comprise of patients who have relapsed or did not respond to treatment and are not eligible for stem cell transplant.
The objective of this registry is to observe short and long term clinical outcomes in heart transplant recipients who receive AlloMap testing as part of allograft rejection surveillance.
This is a study comparing the Defibrotide prophylaxis arm vs standard of care arm for the prevention of aGvHD.
The objective of this study is to demonstrate that treatment with the Barostim neo system, relative to medical management, reduces the rate of cardiovascular mortality or worsening heart failure that leads to hospitalization, cardiac assist device or heart transplant.
This phase III trial studies the side effects and how well risk-based therapy works in treating younger patients with newly diagnosed liver cancer. Surgery, chemotherapy drugs (cancer fighting medicines), and when necessary, liver transplant, are the main current treatments for hepatoblastoma. The stage of the cancer is one factor used to decide the best treatment. Treating patients according to the risk group they are in may help get rid of the cancer, keep it from coming back, and decrease the side effects of chemotherapy.
This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as blinatumomab, may block cancer growth in different ways by targeting certain cells. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.
Evaluation of the Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure With Ejection Fraction Between 25% and 45%: FIX-HF-5C
**This study is not accepting new participants at this time.
The objective of the Continued Access study is to gather confirmatory evidence on the safety of the SonRtip lead and performance of the automatic atrioventricular (AV) delay and interventricular (VV) delay optimization algorithm used in the PARADYM RF SONR Cardiac Resynchronization Therapy with Defibrillation (CRT-D) device (Model 9770) in a patient population that is reflective of current heart failure treatment practice.
This randomized phase III trial compares how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Monoclonal antibodies, such as blinatumomab, can block cancer growth by finding cancer cells and helping to kill them or carrying cancer-killing substances to them. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.
This trial is testing that intensive medical management differs from the combination of CEA and intensive medical management in preventing the primary endpoint in patients with high-grade asymptomatic carotid stenosis and to test that intensive medical management differs from the combination of CAS and intensive medical management in preventing the primary endpoint in patients with high-grade asymptomatic carotid stenosis.
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid "Master Protocol" (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a "non-match" sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.